about
Metformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-AnalysisEconomic Evaluation of Pharmacogenetic Tests in Patients Subjected to Renal Transplantation: A Review of LiteratureWeekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trialReduction behavior induced by HL010183, a metformin derivative against the growth of cutaneous squamous cell carcinoma.Roles of the immune system in skin cancer.Metformin: multi-faceted protection against cancer.A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer.Peripheral administration of translation inhibitors reverses increased hyperalgesia in a model of chronic pain in the rat.A phase I study of the combination of temsirolimus with irinotecan for metastatic sarcomaGlucosamine activates autophagy in vitro and in vivo.Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer.Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment.Metformin targets multiple signaling pathways in cancer.New therapeutic options for metastatic malignant insulinomas.The struggle for energy in podocytes leads to nephrotic syndrome.Temsirolimus: a safety and efficacy review.Autophagy and haematopoietic stem cell transplantation.mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review.Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.Evaluation of the Effect of Everolimus on Retinal Pigment Epithelial Cells and Experimental Proliferative Vitreoretinopathy.Clinical development of mTor inhibitors for renal cancer.The use of sirolimus in the treatment of giant cystic lymphangioma: Four case reports and update of medical therapy.Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
P2860
Q26765139-729D492E-2879-41CB-8FF4-9C5439E82BE2Q28073025-CBF31E7C-953D-454C-8C6F-673E9AD52C85Q33410691-67CCC70E-C8F0-4089-B80D-429EE7D053BAQ35145204-F3CED262-B61F-4B0B-A4FC-73E28626EB82Q35403714-6904E65D-D99A-4370-93AE-9BD7B2E80995Q35764409-4BB3D080-58DE-420C-B6D1-18C94FD52C06Q36557467-3400193F-D8C8-4751-9D70-74FF64CC2889Q36979846-9B35C0E1-13D6-425D-9333-A98DBD652FBBQ37061813-3A250A8D-6188-48A7-B4C4-4AD0B15F74FAQ37168084-B9EDA85F-BDA9-46CA-8A78-64E798284671Q37570653-2CFB6918-249C-4035-BA66-1E270D0CCFA7Q37581359-0C9CF32F-56E5-4CD1-849C-EC01033A7484Q37609790-06622D51-98AC-4785-8A49-D1DA86D530ACQ37886036-6DFFF5F7-FFF1-45CA-B480-6D7E388A5188Q37995467-97AC6E57-A10A-4F67-9B0A-A61E75697364Q38031941-A0E7A46D-A6C2-43FA-BA6F-7A970BF7665BQ38264772-CF860025-0E43-4294-BB31-00624479A164Q38922287-53150C51-2C2F-4DDB-929D-453C345AD0DAQ41689857-E9987FA5-04ED-4DF0-ABF3-2BCEB3D93C90Q47356910-A85BD196-95B6-4A2D-9F43-2748D5D70416Q47737687-AB9EFC87-5F53-46F6-85C0-BD22BA652C4DQ49281445-890D51ED-ED87-4C86-9071-4192F1EE949BQ51122180-F70E8DBF-E0CB-433E-BAB5-79649473FCE7
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhibitors of mTOR.
@en
Inhibitors of mTOR.
@nl
type
label
Inhibitors of mTOR.
@en
Inhibitors of mTOR.
@nl
prefLabel
Inhibitors of mTOR.
@en
Inhibitors of mTOR.
@nl
P2093
P2860
P1433
P1476
Inhibitors of mTOR.
@en
P2093
Heinz-Josef Klümpen
Jan H M Schellens
Jos H Beijnen
P2860
P304
P356
10.1634/THEONCOLOGIST.2010-0196
P577
2010-12-08T00:00:00Z